Baicalin attenuates Alzheimer-like pathological changes and memory deficits induced by amyloid β1–42 protein

Metabolic Brain Disease

Volumn 30, Issue 2, 2015, Pages 537-544

  Chen, Chong ^a   Li, Xiaohong ^a   Gao, Peilong ^a   Tu, Yue ^a   Zhao, Mingliang ^a   Li, Jianwei ^a   Zhang, Sai ^a   Liang, Haiqian ^a  

^a Logistics University of PAP(People s Armed Police)   (China)

Author keywords

Alzheimer s disease; Baicalin; Glial activation; Memory; Neuroinflammation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BAICALIN; CYTOKINE; FLAVONOID; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG EFFECTS; GLIA; IMMUNOHISTOCHEMISTRY; INSTITUTE FOR CANCER RESEARCH MOUSE; MACROPHAGE ACTIVATION; MALE; MAZE TEST; MEMORY DISORDERS; METABOLISM; MOUSE; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION DISORDERS; CYTOKINES; FLAVONOIDS; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NEUROGLIA; PEPTIDE FRAGMENTS;

EID: 84939883314     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9601-9     Document Type: Article

References (47)

1. Aisen PS et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819–2826. doi:10.1001/jama.289.21.2819
2. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K (2000a) Cell mediators of inflammation in the Alzheimer disease brain Alzheimer disease and associated disorders 14 Suppl 1:S47-53
3. Akiyama H et al (2000b) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421
4. Bochorakova H, Paulova H, Slanina J, Musil P, Taborska E (2003) Main flavonoids in the root of Scutellaria baicalensis cultivated in Europe and their comparative antiradical properties. Phytother Res 17:640–644. doi:10.1002/ptr.1216
5. Cai M et al (2011) Neuroprotective effects of a traditional herbal prescription on transient cerebral global ischemia in gerbils. J Ethnopharmacol 138:723–730. doi:10.1016/j.jep.2011.10.016
6. Cheng F et al. (2013) Baicalin’s Therapeutic Time Window of Neuroprotection during Transient Focal Cerebral Ischemia and Its Antioxidative Effects In Vitro and In Vivo Evidence-based complementary and alternative medicine: eCAM 2013:120261 doi:10.1155/2013/120261
7. Choi SH et al (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem 124:59–68
8. Colaianna M et al (2010) Soluble beta amyloid (1–42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br J Pharmacol 159:1704–1715. doi:10.1111/j.1476-5381.2010.00669.x
9. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J biol Chem 277:32046–32053. doi:10.1074/jbc.M201750200
10. Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29:357–365. doi:10.1016/j.it.2008.05.002
11. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12:383–388
12. Heneka MT et al (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain:J neurol 128:1442–1453
13. Huang Z, Yang Y, Li X, Chen X (1999) Plasma and cerebrospinal fluid pharmacokinetics of baicalin in the rabbit model of brain edema. Chin J Contemp Paediatr 11:146–148
14. Ikemoto S, Sugimura K, Yoshida N, Yasumoto R, Wada S, Yamamoto K, Kishimoto T (2000) Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 55:951–955
15. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochem 32:4693–4697
16. Jung SH, Kang KD, Ji D, Fawcett RJ, Safa R, Kamalden TA, Osborne NN (2008) The flavonoid baicalin counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes. Neurochem Int 53:325–337. doi:10.1016/j.neuint.2008.09.004
17. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312–318
18. Kukar TL et al (2008) Substrate-targeting gamma-secretase modulators. Nature 453:925–929. doi:10.1038/nature07055
19. Lee HE et al (2012) Neuroprotective effect of sinapic acid in a mouse model of amyloid beta (1–42) protein-induced Alzheimer’s disease. Pharmacol Biochem Behav 103:260–266
20. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues JF, Barberger-Gateau P (2007) Flavonoid intake and cognitive decline over a 10-year period. Am J Epidemiol 165:1364–1371
21. Li BQ et al (2000) The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacol 49:295–306
22. Liu Y, Chi L, Gao F, Meng X, Zhang Y, Jiang W (2013) Protective effect of baicalin against convulsion induced by pentylenetetrazol in mice Tianjin. J Tradit Chin Med 30:492–494
23. Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430:631–639. doi:10.1038/nature02621
24. McLarnon JG, Ryu JK (2008) Relevance of abeta1-42 intrahippocampal injection as an animal model of inflamed Alzheimer’s disease brain. Curr Alzheimers Res 5:475–480
25. Meral D, Urbanc B (2013) Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid beta-protein. J Mol Biol 425:2260–2275. doi:10.1016/j.jmb.2013.03.010
26. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease The New England. J Med 362:329–344. doi:10.1056/NEJMra0909142
27. Passos GF et al (2010) Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1–40 peptide in mice. Brain Behav Immun 24:493–501
28. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U (2010) Amyloid-beta and mitochondria in aging and Alzheimer’s disease: implications for synaptic damage and cognitive decline Journal of Alzheimer’s disease: JAD 20 Suppl 2:S499-512 doi:10.3233/JAD-2010-100504
29. Reilly JF et al (2003) Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc National Acad Sci United States of Am 100:4837–4842. doi:10.1073/pnas.0330745100
30. Rong Z, Pan R, Xu Y, Zhang C, Cao Y, Liu D (2013) Hesperidin pretreatment protects hypoxia-ischemic brain injury in neonatal rat Neuroscience doi:S0306-4522 (13) 00802-610.1016/j.neuroscience.2013.09.030
31. Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal 2012:756357
32. Sawamura N et al (2000) Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. J Biol Chem 275:27901–27908
33. Schenk D et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177. doi:10.1038/22124
34. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends Biol 8:447–453
35. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
36. Shieh DE, Liu LT, Lin CC (2000) Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res 20:2861–2865
37. Tan J et al (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat Neurosci 5:1288–1293
38. Tu XK, Yang WZ, Shi SS, Wang CH, Chen CM (2009) Neuroprotective effect of baicalin in a rat model of permanent focal cerebral ischemia. Neurochem Res 34:1626–1634. doi:10.1007/s11064-009-9953-4
39. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44:181–193. doi:10.1016/j.neuron.2004.09.010
40. Wang CZ, Mehendale SR, Calway T, Yuan CS (2011) Botanical flavonoids on coronary heart disease. The American journal of Chinese medicine 39:661–671. doi:10.1142/S0192415X1100910X
41. Weggen S et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216
42. Wimo A, Winblad B, Aguero-Torres H, von Strauss E (2003) The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc disord 17:63–67
43. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35:419–432
44. Xue X et al (2010) Baicalin attenuates focal cerebral ischemic reperfusion injury through inhibition of nuclear factor kappaB p65 activation. Biochem Biophys Res Commun 403:398–404
45. Zhang L, Xing D, Wang W, Wang R, Du L (2006) Kinetic difference of baicalin in rat blood and cerebral nuclei after intravenous administration of Scutellariae Radix extract. J Ethnopharmacol 103:120–125. doi:10.1016/j.jep.2005.07.013
46. Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J (2013) Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine 8:3769–3779. doi:10.2147/IJN.S51578
47. Zhou QB, Duan CZ, Jia Q, Liu P, Li LY (2013) Baicalin attenuates focal cerebral ischemic reperfusion injury by inhibition of protease-activated receptor-1 and apoptosis Chinese. J Integr Med. doi:10.1007/s11655-013-1441-7